Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of SACT-1 vs Edurant
NCT05358756Phase 1Completed
- Sponsor
- Aptorum Group Limited
- Start
- Oct 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SACT-1 in neuroblastoma (3 arms), sponsored by Aptorum Group Limited. Primary endpoint: Relative Bioavailability of SACT-1 and Edurant Tablet at 240 hours. Started Oct 2021; status: completed.
02
Drugs
SACT-1
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05358756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358756.